• Thiazovivin: Identity and Documented Scope

  2026-10-19

  Thiazovivin (A5506) is described by APExBIO as a small-molecule ROCK inhibitor associated with fibroblast reprogramming and human embryonic stem cell survival. The supplied evidence is product information rather than a matched research paper, so its claims should be treated as provisional and context-specific.

• HyperTrap Heparin HP Column: Evidence and Scope

  2026-10-19

  APExBIO describes the HyperTrap Heparin HP Column as a preloaded affinity format containing HyperChrom Heparin HP Agarose. The documented architecture supports a heparin-mediated separation concept, but the available product information does not establish target-specific selectivity, binding capacity, recovery, purity, or the claimed resolution advantage through an identity-matched research study.

• Moclobemide (Ro 111163): Evidence and Mechanism

  2026-10-18

  The APExBIO product description identifies Moclobemide (Ro 111163; A4370) as a reversible, preferential monoamine oxidase-A inhibitor and reports biochemical, ex vivo, receptor-binding, and pharmacokinetic properties. Those claims support a conceptual role in antidepressant research and monoamine oxidase inhibition assays, but no identity-matched primary paper is available here. Several reported values require source verification, particularly the internally discordant potency figures and the unspecified models behind the ex vivo and receptor findings.

• A-740003: What the Evidence Establishes

  2026-10-17

  The APExBIO listing identifies A-740003 by name and SKU, but provides no product description, molecular identity, target, mechanism, assay context, or identity-matched research evidence. Accordingly, its scientific scope cannot be extended beyond documented catalog identity.

• Amyloid Beta-Peptide (12-28): Evidence and Scope

  2026-10-16

  The APExBIO product is a defined synthetic 17-residue fragment of human amyloid beta, with supplier-reported identity, purity, analytical verification, and formulation properties. Its proposed relevance to amyloid aggregation and neurotoxicity is a conceptual research scope rather than a demonstrated product-specific biological outcome, because no identity-matched study or comparative dataset is available here.

• Anti-PCBP1 Antibody: Evidence and Scope

  2026-10-16

  The APExBIO listing identifies MA4225 as a rabbit monoclonal antibody directed against PCBP1, but the available product information does not provide an epitope, binding data, application validation, or identity-matched research findings. Its defensible scientific scope is therefore limited to a target-oriented measurement reagent whose performance and biological interpretation remain unestablished in the available evidence.

• Puerarin: Identity, Mechanism, and Evidence Boundaries

  2026-10-15

  APExBIO identifies Puerarin as a kudzu-derived isoflavone with a defined chemical name, CAS number, molecular weight, reported solubility, and supplier quality-control specifications. Its proposed anti-inflammatory, pro-collagen, neuropharmacological, and tissue-repair relevance remains a product-level description rather than evidence from an identity-matched study.

• NF 449: What the 1998 Gαs Study Showed

  2026-10-15

  The cited 1998 PNAS study identified NF 449 as a relatively selective inhibitor of Gαs activation and receptor coupling, not as a platelet P2X1 antagonist. Its evidence came from purified-protein, membrane-reconstitution, and receptor-coupling readouts, while modern platelet-focused claims require separate primary-source verification.

• Cy5 Maleimide: Identity, Mechanism, and Evidence

  2026-10-14

  APExBIO describes Cy5 maleimide (non-sulfonated), SKU A8139, as a mono-reactive cyanine dye for thiol-directed labeling of peptides and proteins, primarily at cysteine residues. Its listed spectral properties support fluorescence-based detection, but the available material is a product description rather than an identity-matched research study, so it does not establish labeling efficiency, selectivity in particular proteins, assay performance, or comparative superiority.

• MOG (35-55) and PARP7 in EAE Research

  2026-10-14

  MOG (35-55) provides an antigenic framework for experimental autoimmune encephalomyelitis research, while a 2025 Cell Reports study links PARP7 to suppression of type I interferon signaling through STAT1/STAT2 regulation. The findings are mechanistically informative but remain preclinical and model-dependent, with important limits on their relevance to human multiple sclerosis.

• Interpreting a Bivalent Avian Flu mRNA Vaccine Study

  2026-10-13

  Wei et al. report broad protective signals from a bivalent H5/H7 mRNA–LNP vaccine in SPF chickens, but the evidence remains pre-field and does not establish durability, transmission control, comparative superiority, or performance in diverse commercial poultry settings.

• CP-673451 and ATRX-Deficient Glioma Evidence

  2026-10-13

  A source-grounded overview of CP-673451 as a reported selective PDGFRα/β inhibitor, the ATRX-associated glioma findings, and the limits of translating supplier-reported pharmacology or cell-based sensitivity into broader cancer conclusions.

• PTX, Neonatal Monocytes, and Apoptosis Readouts

  2026-10-12

  Schüller et al. reported that pentoxifylline dampened several LPS-responsive monocyte functions in an in-vitro comparison of preterm infants, term infants, and adults. The study did not report Annexin V measurements or establish whether the observed immune changes reflected altered inflammatory signaling, reduced phagocytic activity, cell death, or a combination of these processes. An Annexin V-PE assay is therefore conceptually relevant to the distinction between phosphatidylserine exposure and inflammatory phenotype, but it is not evidence that the cited study used the APExBIO product or measured apoptosis.

• Brassinolide, Light, and Arabidopsis Root Growth

  2026-10-12

  A 2026 Arabidopsis study reports that light and brassinosteroids affect seedling root elongation in largely separable ways, while also revealing context-dependent responses to the biosynthesis inhibitor brassinazole. The findings are limited to an early developmental stage, a single model species, selected genetic backgrounds, and a root-length endpoint. Supplier-page claims concerning 24-Epibrassinolide, apoptosis, cancer research, and diabetes research are not independently substantiated by the supplied primary literature.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages

  2026-10-11

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic regulator of tumor-associated macrophages. The study links lysosomal 25-hydroxycholesterol to AMPKα–STAT6 signaling, ARG1 production, immune suppression, and improved anti-tumor responses after CH25H targeting. The findings are mechanistically suggestive but remain bounded by model context, correlative human analyses, and the absence of evidence connecting the work to Oligomycin A.

555 records 1/37 page Next 12345 下5页 Last page